Skip to main content
Premium Trial:

Request an Annual Quote

Ciphergen to Market ProteinChip in China

NEW YORK, Feb. 19 - Ciphergen Biosystems has gained a toehold in China after it sold its ProteinChip systems to hospitals, universities, and government agencies in that country, the company said on Tuesday. 


Ciphergen has also established a formal relationship with the Universities Confederated Institute for Proteomics, which the Chinese government established in May 2001. 


"The Chinese government has publicly stated that it intends to foster proteomics research and China is therefore potentially a very significant market for Ciphergen," William E. Rich, president and CEO of the Fremont, Calif.-based company, said in a statement.


Dacheng He, chief scientist and deputy director of UCIP, commented that he is "optimistic" that his group will be able to discover "a number of protein biomarkers that will be useful as predictive diagnostics, as well as providing insights into disease pathways."


Ciphergen's ProteinChip system is designed to be used for protein discovery, characterization, and assay development. 

The Scan

Positive Framing of Genetic Studies Can Spark Mistrust Among Underrepresented Groups

Researchers in Human Genetics and Genomics Advances report that how researchers describe genomic studies may alienate potential participants.

Small Study of Gene Editing to Treat Sickle Cell Disease

In a Novartis-sponsored study in the New England Journal of Medicine, researchers found that a CRISPR-Cas9-based treatment targeting promoters of genes encoding fetal hemoglobin could reduce disease symptoms.

Gut Microbiome Changes Appear in Infants Before They Develop Eczema, Study Finds

Researchers report in mSystems that infants experienced an enrichment in Clostridium sensu stricto 1 and Finegoldia and a depletion of Bacteroides before developing eczema.

Acute Myeloid Leukemia Treatment Specificity Enhanced With Stem Cell Editing

A study in Nature suggests epitope editing in donor stem cells prior to bone marrow transplants can stave off toxicity when targeting acute myeloid leukemia with immunotherapy.